Cerevel Therapeutics Holdings, Inc.

CERE · NASDAQ
Analyze with AI
3/31/2024
12/31/2023
9/30/2023
6/30/2023
Operating Activities
Net Income-$132-$133$8-$10
Dep. & Amort.$2$2$1$1
Deferred Tax$0-$28-$108-$94
Stock-Based Comp.$21$25$17$15
Change in WC-$5$9$17$1
Other Non-Cash-$5$28-$8$10
Operating Cash Flow-$120-$97-$73-$77
Investing Activities
PP&E Inv.-$0-$1-$1-$2
Net Acquisitions$0$0-$0-$0
Inv. Purchases-$123-$317-$213-$147
Inv. Sales/Matur.$142$168$265$211
Other Inv. Act.$0-$0$0$0
Investing Cash Flow$19-$150$51$62
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued-$0$508$1$6
Stock Repurch.-$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$4$508$1$38
Financing Cash Flow$4$508$1$38
Forex Effect$0$53$28-$32
Net Chg. in Cash-$96$314-$20$22
Supplemental Information
Beg. Cash$418$677$178$156
End Cash$322$991$158$178
Free Cash Flow-$120-$98-$73-$79